9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

Dermatitis Herpetiformis (DH, Duhring's Disease)

Dermatitis herpetiformis (DH) is an intensely pruritic, chronic, polymorphic autoimmune blistering dermatosis that serves as the specific cutaneous manifestation of gluten-sensitive enteropathy (coeliac disease). First described by Louis Duhring in 1884, DH represents an immunologically driven model of mucosal tolerance breakdown and gut-skin cross-talk.

Immunopathogenesis & The Gut-Skin Axis

• Genetic Architecture: Like coeliac disease, DH exhibits the strongest human leukocyte antigen (HLA) class II genetic association known in dermatology:
  • HLA-DQ2.5 (encoded by alleles $DQA105:01$ and $DQB102:01$) is present in 90% to 95% of patients.
  • HLA-DQ8 (encoded by alleles $DQA103:01$ and $DQB103:02$) is present in the remaining 5% to 10%.
  • An individual who lacks both HLA-DQ2 and HLA-DQ8 has an essentially zero probability of developing dermatitis herpetiformis (negative predictive value >99%).
• The Mucosal Trigger: Ingestion of dietary gluten (wheat gliadin, barley hordein, and rye secalin). Gliadin peptides resist complete proteolytic digestion by gastric and pancreatic enzymes. Proline- and glutamine-rich 33-mer gliadin peptides cross the intestinal epithelial barrier into the lamina propria.
• Transglutaminase Enzymatic Deamidation: In the gut, tissue transglutaminase (tTG / TG2) enzymatically deamidates glutamine residues in gliadin into negatively charged glutamic acid. This modification drastically increases gliadin peptide binding affinity to positively charged peptide-binding grooves of HLA-DQ2/DQ8 heterodimers on antigen-presenting dendritic cells.
• Autoantibody Generation & Epitope Spreading: Antigen presentation stimulates CD4+ T helper cells (Th1 and Th17), driving mucosal B-cell clonal expansion and synthesis of IgA autoantibodies directed against tTG. Through B-cell intramolecular and intermolecular epitope spreading, autoantibodies develop against epidermal transglutaminase (eTG / TG3), an enzyme expressed in epidermal spinous keratinocytes involved in cornified envelope assembly.
• Dermal Papillae Immune Complex Deposition: High-affinity circulating IgA-TG3 immune complexes deposit selectively within the tips of dermal papillae in the skin, where they bind to dermal fibrinogen and extracellular matrix microfibrils. These immune complexes activate complement (C3a and C3b generation), triggering local release of IL-8 and leukotriene B4 ($LTB_4$). Neutrophils expressing high levels of the Fc-alpha receptor I (CD89) are recruited to the dermal papillae tips, releasing elastase, matrix metalloproteinases, and reactive oxygen species that cleave the lamina lucida, culminating in subepidermal blister separation.

Clinical Presentation of Dermatitis Herpetiformis

• Symptom Hallmark: Characterized by excruciating, intense, burning, stinging, and lancinating pruritus. The itching is so severe and distinctive that patients frequently describe a painful sensation of "hot needles" or burning prior to any visible skin lesion erupting.
• Morphology: The primary eruption is classically polymorphic: grouped, tiny, clustered vesicles resembling herpes simplex (hence the historical moniker herpetiformis), alongside erythematous urticarial papules and small wheals.
• Secondary Excoriations: Because the pruritus is intolerable, patients vigorously excoriate and scratch the skin. Consequently, intact primary vesicles are rarely observed in clinical practice. The patient typically presents with grouped, excoriated crusts, erosions, and post-inflammatory hypopigmentation or hyperpigmentation.
• Anatomical Distribution: Strikingly symmetrical predilection for the extensor surfaces of the body:
  • Extensor elbows (olecranon prominence) and dorsal forearms.
  • Knees (patellar region) and pretibial shins.
  • Buttocks, sacrum, and natal cleft.
  • Upper back, posterior shoulders, and posterior scalp / nape of neck.
  • Mucous membrane involvement is virtually non-existent.

Intestinal Pathology and Malignancy Risk

• Coeliac Enteropathy: Virtually all patients with dermatitis herpetiformis have gluten-sensitive small bowel enteropathy (around three-quarters show villous atrophy on duodenal biopsy; the rest show milder changes), ranging from mild Marsh I (intraepithelial lymphocytosis) to Marsh III (crypt hyperplasia with partial or total villous atrophy).
• The "Silent" Gut Trap: Although enteropathy is universal, over 70% to 80% of DH patients have no overt gastrointestinal symptoms (no chronic diarrhea, bloating, or abdominal cramping). The absence of bowel complaints does NOT rule out DH or coeliac disease.
• Enteropathy-Associated T-Cell Lymphoma (EATL): Patients with untreated DH or poor dietary compliance carry an elevated relative risk of developing Enteropathy-Associated T-Cell Lymphoma (EATL), a highly aggressive intestinal non-Hodgkin lymphoma arising from intraepithelial T lymphocytes in the jejunum. Strict adherence to a lifelong gluten-free diet reverses intestinal mucosal inflammation, restores normal villous architecture, and, in cohort studies, appears to reduce the elevated lymphoma risk.

Diagnostic Workup in Dermatitis Herpetiformis

1. Direct Immunofluorescence (DIF) — The Diagnostic Gold Standard:

   • Biopsy Site Selection (Critical Technical Rule): The punch biopsy for DIF MUST be taken from perilesional, normal-appearing skin (1 to 2 cm adjacent to an active lesion). If the biopsy is mistakenly taken from an active blister or erosion, the massive influx of activated neutrophils will enzymatically degrade the bound IgA via elastase release, producing a false-negative DIF result.
   • DIF Pattern: Shows continuous or discontinuous granular deposits of IgA concentrated within the tips of the dermal papillae (fibrillar or granular pattern). Less commonly, granular IgA is deposited in a continuous band along the basement membrane zone. C3 is co-deposited in 50% of cases.

2. Histopathology (Routine H&E):

   • Biopsy of an early, intact erythematous papule or edge of a microvesicle demonstrates neutrophilic microabscesses clustered at the tips of dermal papillae. Accompanied by edema, fibrin deposition, leukocytoclasia, and occasional eosinophils. Confluence of microabscesses leads to subepidermal clefting at the lamina lucida.

3. Serological Testing:

   • IgA Anti-Epidermal Transglutaminase (Anti-eTG / Anti-TG3) ELISA: Highest sensitivity (>95%) and specificity (>98%) for dermatitis herpetiformis. Titer levels reflect cutaneous disease activity and dietary compliance.
   • IgA Anti-Tissue Transglutaminase (Anti-tTG / Anti-TG2) ELISA: High sensitivity; standard first-line coeliac screening test.
   • IgA Anti-Endomysial Antibodies (EMA): Detected by indirect immunofluorescence on primate esophagus (reticular staining of smooth muscle endomysium); extraordinarily high specificity (>99%).
   • Mandatory Serum Total IgA Determination: Selective IgA deficiency occurs at a 10- to 15-fold higher frequency in coeliac/DH patients (approx. 2–3% prevalence) than in the general population. In IgA deficiency, all IgA-based serologies (anti-tTG, anti-TG3, EMA) are falsely negative. If total serum IgA is subnormal, the clinician must order IgG anti-tTG, IgG anti-deamidated gliadin peptides (DGP), and IgG anti-TG3.

European Management Protocol: Dietary vs Pharmacological Strategy

Management rests on a dual strategy: life-saving dietary modification coupled with rapid-acting pharmacotherapy.

                                 Dermatitis Herpetiformis Management
                                                  │
                 ┌────────────────────────────────┴────────────────────────────────┐
                 ▼                                                                 ▼
   Lifelong Gluten-Free Diet (GFD)                                    Dapsone Pharmacotherapy
  - Curative & Disease-Modifying                                     - Rapid Symptomatic Control
  - Heals small bowel villous atrophy                                - Suppresses burning/itching in 24–48h
  - Prevents intestinal T-cell lymphoma                              - ZERO effect on bowel pathology
  - Clears cutaneous IgA slowly (1–2 yrs)                            - Mandatory pre-treatment G6PD screening

1. Strict Lifelong Gluten-Free Diet (GFD):

   • The ONLY curative and disease-modifying treatment. Involves complete dietary exclusion of wheat, barley, and rye. Pure, uncontaminated oats are tolerated by the majority of patients.
   • Divergent Recovery Kinetics: While gastrointestinal mucosal architecture normalizes within 6 to 12 months, cutaneous IgA deposits clear extraordinarily slowly. Skin lesions require 1 to 2 years of strict GFD to resolve completely without medication. Patients must be counseled that even minor dietary indiscretions (e.g., a single crouton) can prompt an explosive cutaneous relapse within 24 to 72 hours.

2. Dapsone (Diaminodiphenylsulfone):

   • Mechanism: A sulfone antibiotic that potently suppresses neutrophil myeloperoxidase, inhibits neutrophil chemotaxis, and blocks integrin-mediated neutrophil adhesion and lysosomal enzyme release. Dapsone has zero effect on intestinal pathology and does not reduce lymphoma risk.
   • Clinical Efficacy: Produces dramatic, miraculous relief of burning and itching within 24 to 48 hours, with complete cessation of new blister formation within 72 hours. Serves as a diagnostic therapeutic trial.
   • Dosing: Initiated at 50 mg daily, titrated upward to 100 to 150 mg/day until symptoms are arrested, then tapered to the lowest effective maintenance dose (often 25–50 mg twice weekly) as the gluten-free diet takes effect over 1 to 2 years.
   • Mandatory Pre-Treatment Screening:
     • Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency: Mandatory prior to writing the first dapsone prescription. In G6PD-deficient erythrocytes, dapsone's toxic N-hydroxy hydroxylamine metabolites cannot be reduced by glutathione, precipitating life-threatening, massive acute intravascular hemolytic crisis.
   • Predictable & Idiosyncratic Adverse Effects:
     • Dose-Dependent Hemolysis & Methemoglobinemia: Every patient taking dapsone experiences mild, predictable, dose-dependent oxidative hemolysis and methemoglobinemia (Fe2+ oxidized to Fe3+, shifting the oxygen-hemoglobin dissociation curve to the left and impairing tissue oxygenation). Standard pulse oximeters measure falsely low (reading ~85%); co-oximetry on arterial blood gas is required for accurate quantification. Cimetidine (which inhibits CYP2C9 conversion of dapsone to hydroxylamine) reduces methemoglobin levels.
     • Agranulocytosis: Rare (1 in 2000 to 5000), idiosyncratic, potentially fatal; typically arises within the first 2 to 12 weeks of treatment. Complete blood counts must be monitored every 2 weeks for the first 3 months.
     • Dapsone Hypersensitivity Syndrome (DHS / DRESS): Fever, exfoliative dermatitis, generalized lymphadenopathy, hepatitis, and eosinophilia.
     • Distal Motor Neuropathy: Rare, late complication causing motor weakness (e.g., hand weakness, wrist drop) without sensory loss.

3. Alternative Therapies (in Dapsone-Intolerant Patients):

   • Sulfasalazine (1.0–4.0 g/day), Sulfapyridine (1.0–2.0 g/day), or Sulfamethoxypyridazine.

Linear IgA Bullous Dermatosis (LABD)

Linear IgA bullous dermatosis is an acquired, autoimmune, subepidermal blistering disorder mediated by homogeneous, linear deposition of IgA autoantibodies along the basement membrane zone.

Epidemiology & Clinical Phenotypes

Two distinct clinical presentations are recognized:

1. Chronic Bullous Disease of Childhood (CBDC):
   • Peak onset occurs in preschool children between 2 and 5 years of age.
   • Follows a relatively benign, self-limiting course, typically remitting spontaneously within 2 to 4 years.
   • Blister distribution shows a predilection for the lower abdomen, perineum, genitalia, perioral face, and inner thighs.
2. Adult Linear IgA Bullous Dermatosis:
   • Most adult cases begin after 60 years (overall, LABD has a bimodal age distribution: preschool children and older adults).
   • Eruption involves the extensor limbs, trunk, face, and scalp.
   • Mucosal Involvement (up to 50%): Can produce painful desquamative gingivitis, oral ulcerations, and progressive conjunctival scarring mimicking cicatricial pemphigoid.

Morphological Hallmark: The "String-of-Pearls" Configuration

The pathognomonic clinical feature of LABD is the eruption of tense, clear or hemorrhagic vesicles and bullae arranged in an annular, polycyclic, or rosette-like pattern. Characteristically, new blisters erupt along the active erythematous periphery of resolving central crusted lesions—a classic morphology termed the "crown of jewels" or "string-of-pearls" sign.

Molecular Target Antigens

The circulating IgA autoantibodies in LABD target neoepitopes on soluble fragments of the extracellular ectodomain of BP180 (type XVII collagen), which are shed following physiological physiological proteolytic cleavage by ADAM-family metalloproteinases:

• LAD-1 (120 kDa): The full-length shed soluble ectodomain of BP180.
• LABD97 (97 kDa): A truncated carboxy-terminal fragment derived from LAD-1.

Drug-Induced Linear IgA Bullous Dermatosis

LABD has the highest frequency of drug causation among all autoimmune bullous diseases:

• The Hallmark Culprit: Vancomycin. Intravenous vancomycin is responsible for >50% of all drug-induced LABD cases worldwide. Eruptions typically emerge 1 to 15 days after initiating vancomycin therapy.
• Clinical Presentation: Often severe, widespread, and explosive, frequently mimicking toxic epidermal necrolysis (TEN) or erythema multiforme with sheet-like epidermal sloughing.
• Other Culprit Medications: Non-steroidal anti-inflammatory drugs (diclofenac, naproxen), captopril, ceftriaxone, amiodarone, phenytoin, and lithium.
• Resolution: Withdrawal of the offending drug leads to rapid cessation of new blistering within 48 to 72 hours, with complete cutaneous healing over 2 to 6 weeks without recurrence.

Diagnostic Distinction & Management

• Direct Immunofluorescence (DIF): Diagnostic hallmark. Shows continuous, homogeneous, linear IgA deposition along the basement membrane zone. (Distinguishes LABD from the granular IgA of dermatitis herpetiformis and the linear IgG/C3 of bullous pemphigoid).
• Histopathology: Subepidermal blister with a dense neutrophilic infiltrate aligned along the BMZ and in dermal papillae tips, histologically indistinguishable from early dermatitis herpetiformis.
• First-Line Therapy: Dapsone (50–150 mg/day in adults; 1–2 mg/kg/day in children) after confirming normal G6PD status. Corticosteroids can be co-administered in refractory cases.

Differential Diagnosis of Immunobullous Diseases